30 closest matches · ranked by relevance
Improve Endothelial Function and Decrease Vascular Stenosis
Primary: Change in Baseline and 2 Week FMD/VP Measurements Between Sildenafil Group and Placebo Group — 10.8; 8.6 Change in FMD%
End-Stage Renal Disease (ESRD)
Primary: Number of Participants With Adverse Events (AEs) — 8 participants
Chronic Kidney Disease
Primary: Patient Activation Measure (PAM) -13 Item Questionnaire — 9.1; -1.4 points — p=0.01
Anemia · End Stage Renal Disease (ESRD)
Primary: Change From Baseline (BL) to the Average Hemoglobin (Hb) in Weeks 28-36 Without Rescue Therapy [EU (EMA)] — 0.428; 0.193 g/dL — p=<0.001
End Stage Renal Disease on Hemodialysis (Diagnosis)
Primary: Percentage of Subjects Reporting Clinically Significant Adverse Events - Medically-attended Adverse Events, Serious Adverse Events, and Immune-mediated Adverse Events of…
ESRD
Primary: Change in Leucine Disposal Rate (LDR) — -0.011; 0.005; 0.001 mg/kg/min — p=0.37
Chronic Kidney Disease
Primary: Maximal Oxygen Uptake — 14.5; 15.1 ml/kg/min
Chronic Kidney Disease
Primary: Mortality — 0; 0 percentage of mortality
End Stage Renal Disease · Anemia
Primary: Number of Participants With Week 7 Hb ≥ Baseline Hb - 0.5 g/dL, Among Normoresponder Participants Treated for 6 Weeks Only — 4; 8; 7; 4 Participants — p=1.0000
Hyperphosphatemia · End-stage Renal Disease · Renal Failure Chronic Requiring Hemodialysis
Primary: The Primary Outcome of This Trial Will be the Change in Serum Phosphorus From Baseline to End of Treatment After a Four Week Treatment Period. — -1.53 mg/dL
End Stage Renal Disease
Primary: Number of Participants With Mean PTH ≤ 300 pg/mL — 262; 41 Participants — p=<0.001
End-Stage Renal Disease
Primary: Change in Monocyte VDR Expression With Vitamin D Therapy — 1899 units on a scale
Chronic Kidney Diseases · Hypertension · Diabetes
Primary: Number of Participants With CKD Diagnosis — 417; 389 Participants — p=.21
Kidney Disease, End-Stage
Primary: Symptoms - Trajectory of Change — 77.2; 76.2 score on a scale — p=0.30
Hypertension · End Stage Renal Disease
Primary: Change in Mean Interdialytic 44-hour Ambulatory Systolic Blood Pressure Over a 2 Week Follow-up Period — -1.5; -3.7; -0.4 mm Hg
Anaemia
Primary: Area Under the Concentration-time Curve (AUC) Over the Dosing Interval (AUC[0-tau]) of GSK1278863 and Its Metabolites — 184.9863; 138.6511; 162.9366; 131.2826 Hour into…
End Stage Renal Disease
Primary: Reduction Ratio of Lambda Immunoglobulin FLC at Week 24 — 32.156; 17.514 percentage ratio
Hepatitis C, Chronic
Primary: Percentage of Participants With Sustained Virological Response (SVR) at 24 Weeks After End of Treatment — 39.5; 34.9 percentage of participants — p=0.6746
Chronic Kidney Disease
Primary: Preference for Shared Decision Making — 22; 19; 35; 44 participants
End-stage Renal Disease (ESRD)
Primary: Number of Participants With Major Bleeding (MB) and Clinically Relevant Non-Major Bleeding (CRNMB) — 3; 2; 3; 3 Participants
Renal Insufficiency, Chronic
Primary: Number of Participants With Sufficient Patency for Clinical Access — 20 Participants
End-stage Renal Disease (ESRD)
Primary: Peak Oxygen Consumption — 3.07 ml/min/kg
Hyperphosphatemia · End-stage Renal Disease
Primary: The Difference in Serum Phosphorus Between Baseline (Day 0) and End of Treatment (Day 28) — 5.9; 5.4 mg/dL
Chronic Kidney Diseases · Patient Requiring Heparin Free Dialysis Treatments
Primary: The Primary Endpoint is the Number and Percent (%) of Successful Heparin-free HD Sessions for Each Subject in Each Circuit. — 2.4; 2.9 number of successful HD sessions
End Stage Renal Disease · Thrombosis
Primary: The Number of Subjects With Treatment-related Adverse Events (TEAEs) and the Number of TEAEs Will be Summarized Using Frequency Counts (Safety and Tolerability) — 0; 0…
End Stage Renal Disease · Kidney Failure · Renal Failure
Primary: Safety Parameters — 142; 35; 75; 0 participants
Kidney Failure, Chronic
Primary: Change From Baseline in PRA — -0.706; -2.176; -1.688; -2.353 percentage of population — p=0.324
Chronic Kidney Diseases
Primary: The Patient Activation Measure (PAM) — 60.8; 61.5; 1.73; 3.44 score on a scale
Anemia · Secondary Hyperparathyroidism
Primary: Number of Participants With a Mean Intact Parathyroid Hormone Value Between 150 and 300 pg/mL and a Calcium - Phosphorus Product Value < 55 mg^2/dL^2 — 30 Participants
Kidney Failure, Chronic
Primary: Kidney Disease Quality — 75.4; 78.3; 78.4; 73.4 score on a scale